Your Health, We Care
Release date: 2026-05-06 11:24:21 Article From: Lucius Laos Recommended: 15
Finerenone contains the active ingredient Finerenone. This medicine is subject to additional monitoring to allow quick identification of new safety information. You can help by reporting any side effects you may experience. Before you start taking this medicine, please read the package leaflet carefully as it contains important information. Keep the leaflet and consult your doctor or pharmacist if you have any questions. This medicine has been prescribed for you personally; do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If you experience any side effects (including those not listed), please contact your doctor or pharmacist.
Finerenone works by blocking the effects of certain hormones (called mineralocorticoids) that can damage the kidneys and heart. When these hormones are overactive in the body, they cause progressive damage to the kidneys and cardiovascular system. As a selective mineralocorticoid receptor antagonist, Finerenone effectively inhibits this harmful effect, thereby slowing disease progression.
Finerenone is used to treat adults with chronic kidney disease associated with type 2 diabetes. Chronic kidney disease is a long-term condition in which the kidneys gradually lose their ability to remove waste products and fluid from the blood. Type 2 diabetes is a condition in which the body cannot maintain normal blood sugar levels, either because it does not produce enough insulin or cannot use insulin properly, leading to elevated blood sugar levels. This medicine is indicated for use when there is an abnormal amount of the protein albumin in the urine, indicating that the kidneys are already damaged.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3002025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5172024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3002025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3142025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2882025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3412025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2922025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2702025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
